The MedSurg division, which includes endoscopy, urology, and neuromodulation devices, had a 10% revenue rise to $1.48 billion. Boston Scientific Lowers FY EPS Outlook, Raises Adjusted EPS The ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Boston Scientific (NYSE: BSX ... while Cardiovascular sales increased 25% from the same period a year ago. Endoscopy (7.8% growth), Urology (10.3%) and Neuromodulation (17%) drove MedSurg.

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Boston Scientific is launching the Farawave Nav ablation catheter and Faraview software to treat atrial fibrillation in the U.S. · MedTech Dive · Courtesy of Boston Scientific Boston Scientific ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...

The Farapulse Farawave catheter and Faraview software. [Image courtesy of Boston Scientific] Boston Scientific (NYSE: BSX) + announced today that it received FDA approval for its navigation ...

Neuromodulation led the way with a 17% increase. Urology (10.3%) and Endoscopy (7.8%) followed. Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported ...